![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel disease
Publisher: John Wiley & Sons Inc
E-ISSN: 1365-2036|47|6|753-762
ISSN: 0269-2813
Source: ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol.47, Iss.6, 2018-03, pp. : 753-762
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract